# Korea Comirnaty Post-marketing Surveillance

> **NCT05032976** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 12000 (estimated)

## Conditions studied

- COVID-19
- Vaccines
- Adverse Effects
- SARS-CoV-2
- Safety

## Interventions

- **BIOLOGICAL:** Tozinameran 12 Years of age and older
- **BIOLOGICAL:** Tozinameran 5 to 11 Years of age
- **BIOLOGICAL:** Tozinameran 6 months to 4 years of age
- **BIOLOGICAL:** Riltozinameran 12 Years of age and older
- **BIOLOGICAL:** Famtozinameran 12 Years of age and older
- **BIOLOGICAL:** Famtozinameran 5 to 11 Years of age
- **BIOLOGICAL:** Raxtozinameran 12 years of age and older
- **BIOLOGICAL:** Raxtozinameran 6 months to 4 years of age

## Key facts

- **NCT ID:** NCT05032976
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-18
- **Primary completion:** 2027-01-24
- **Final completion:** 2027-01-24
- **Target enrollment:** 12000 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05032976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05032976, "Korea Comirnaty Post-marketing Surveillance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05032976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*